Bremelanotide's Efficacy for Low Sexual Desire in Premenopausal Women Studied

Hypoactive Sexual Desire Disorder (HSDD) is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. It is a common condition affecting many women, yet treatment options remain limited. This Phase 3 study was designed to rigorously evaluate the efficacy and safety of Bremelanotide as a potential new treatment, specifically addressing the need for effective pharmacological interventions for premenopausal women experiencing HSDD.

This Phase 3 trial was designed to rigorously assess the efficacy and safety of Bremelanotide, a melanocortin receptor agonist, in premenopausal women experiencing Hypoactive Sexual Desire Disorder (HSDD). While the provided abstract details the study's robust design, including its randomized, double-blind, placebo-controlled methodology, it does not include specific quantitative results regarding changes in sexual desire, distress, or adverse events. The primary objective was to determine if Bremelanotide, administered on an as-needed basis, could significantly improve these key indicators compared to placebo. The overarching goal of this comprehensive study, completed in June 2017, was to establish a clear efficacy and safety profile for Bremelanotide as a potential treatment for HSDD in its target population, paving the way for regulatory review.